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Introduction 
The evolution and refinement of surgical techniques, perioperative patient care 
and immunosuppression has established orthotopic liver transplantation (OL TX) as a 
highly successful1t1erapeutic modality for patients with end-stage liver disease 1-7. In 
February of 1989, Tacrolimus (Prograf®, formerty FK 506 ) was first used successfully 
at the University of Pittsburgh Medical Center to treat patients with rejection refractory 
to cyclosporine based immunosuppressions. Clinical trails utilizing Tacrolimus in solid 
organ transplanta:on followed and in April of 1 S':l4 it was approved for use by the 
Food and Drug ACl1inistration 9-11. 
In 1989 the Veterans Administration (VA) recognized the need for a national 
center for liver transplantation for U.S. veterans in need of such care. With the 
guidance and efforts of Dr. Thomas Starzl and others, one center was established in 
Pittsburgh, affiliated with the University of Pittsburgh (Pittsburgh Transplantation 
Institute). Since October of 1989 a consecutive series of veterans have been 
transplanted under primary Tacrolimus based immunosuppression 12-14. In this 
chapter, we wish to present our overall results for OL TX in this unique, high risk 
patient population. In addition, we have found an inordinately high incidence of native 
portal vein thromoosis in our veterans undergoing transplantation and will discuss the 
perceived risk factors and surgical approach to these patients 14. Lastly, end-stage 
liver disease due to hepatitis C has been documented in 53% of patients undergoing 
transplantation at the Pittsburgh VA between 1989 and 1995 15. Herein we will also 
discuss the implication of disease recurrence and current approach to therapy for 
recurrent disease. 
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Five Year Experience with Tacrolimus in U.S. Vetetans 
Undergoing Uver Ttansplantation 
United States veterans represent a unique patient population compared to the 
demographics reported from other transplant centers here in the United States as well 
as in Europe 15-18. This predominantly male, older population has a high prevalence of 
end-stage liyer disease secondary to hepatitis (8 and/or C) and toxin induced liver 
disease or combinations thereof. This comt~ned with other factors presents a 
significant therapeutic chalienge which we believe adds further supportive testimony to 
the efficacy of liver transplantation in high risk patients 19,20. 
Patients and Methods 
Between October 1989 to October 1995 140 OL TX were performed in 130 
consecutive U.S. veterans under a primary Tacrolimus based immunosuppressive 
PiOtoCOI. There were 128 (98%) males and 2 (2%) females with a mean age of 47.3 
years (range 22-70). There were 15 patients (11.5%) over the age of 60 (all male). 
The etiology of underlying fiver disease is shown in Table 1. The mean follow-up of 
this patient series is 36.6 months with a range of 3 to 74 months. Other pre-
transplant patient factors and morbidity are shown in Table 2. It is notable that the 
number of patients with abnormal renal function (creatinine ~ 2.0) was somewhat high 
and the overall patient profile reflects a high risk group. 
The immunosuppressive protocol utilized was identical to that of the University 
of Pittsburgh with much higher initial doses of Tacrolimus in the early group. At 
present we initiate Tacrolimus intravenously at a dose of 0.025 - 0.05 mg/kg over 24 
hours after reprefusion along with a bolus c: 1 gm of Methylprednisolone. The amount 
of Tacrolimus administered was largely dependent upon pre-operative renal function 
and/or urinary output in the first 24 hours after graft reprefusion. Prednisone was 
given at a dose of 20 mg per day with gradual reduction of dosage over three to 12 
weeks in absence of any proven rejection. Imuran was used in 14 patients (short-
term) with nephrotoxicity or perceived neurotoxicity and 3 patients were left on long-
term therapy. At present 58% of patients are free of steroids. Rejection episodes 
were routinely treated with increasing maintenar..:e Tacrolimus therapy and a 1 gm 
bolus of Methylprednisolone. Less commonty, patients not responding to this received 
Methylprednisolor-e re-cycles (tapering cose ste-uid therapy starting at 200 mg 
intravenous daily 1020 mg per day over 5 days)_ OKT3 (Orthoclone®) was used for 
steroid resistant rejection. 
Results 
The actuarial patient survival rates were 90%, 87%, 85%, and 80% at 6, 12, 24 
and 60 months respectively (Figure 1). Graft SlJ'Vival was 86%, 83%, 76% and 70% 
at 6, 12, 24 and 60 months respectively_ Ten patients (8%) were re-transplanted with 
a long-term actuarial survival rate of 50%. 
Additional il1munosuppression was required in the first six months post-
transplant in 53 patients (41%). Forty 0: these patients had biopsy proven rejection 
episodes wereas the remainder were clinical diagnoses. Forty-five patients (35%) 
received additional steroid boluses (1 gr Methylprednisolone) while an additional 26 
patients (20%) required steroid re-cycles. Only one patient (1 %) received OKT3 for 
steroid resistant rejection within the first six morths post-OL TX. OKT3 was required 
for two episodes of late rejection (at ap;:mximately 1 and 2 years post-OL TX) 
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attributable to malabsorption of FK 506 in one patient with inflammatory bowel disease 
and an inadequate maintenance dose in the remaining patient. Both of these patients 
recovered from their rejection episodes and are currently alive and well with normal 
allograft function. These results compare favorably with recently reported multi-center 
trials and with those at the University of Pittsburgh Medical Center 11,18,19. 
Although FK 506 is a potent immunosuppressive agent it does not appear to be 
associated with a higher incidence of infectious complications compared to previous 
studies with cyclosporine-based immunosuppressive protocols 22-27. The range of 
reported infectious complications in these studies is 47 - 83% with the incidence of 
major infections being reported as ranging between 57% and 67%. In our updated 
series we have observed at least one major infection in 58 (45%) of our patients. 
Major bacterial infections accounted for the majority of significant post-
transplant infectious morbidity with 45 patients (34%) having at least one major 
bacterial infection (Table 3). The median time of onset for these episodes was 35.5 
days with a relatively low incidence of intra-abdominal sources. 
Pulmonary infections have been reported in 13-32% of the liver transplant 
recipients in the previous reports and account for 16 to 49% of major infections these 
patients pneumonias occurred in 15% of the patients; 27% of the episodes of major 
infections in our patients were due to pneumonia. None of the patients had 
cytomegalovirus or Pneumocystis carinii pneumonia. Thirty-seven percent (7/19) 
episodes of pneumonia were due to fungi ie. Aspergillus and Cryptocococcus, 
Legionella species accounted for 27% of the bacterial pneumonias. 
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Major fungal infections were seen in 14 (11 %) of our patients (median onset 
188 days post-OL TX). This compares favorably with what is generally reported in the 
literature of 16 to 24% 28-29. Pay a et al. observed a low incidence (4%) of fungal 
disease in their patients and this was partly attributed to a policy of peri-operative 
seledive enteral decontamination 22. we utilize a similar regimen however it is given 
after OL TX and only until the patient is no longer ventilator dependent. We have 
notec in o~r updated series that Candida and Aspergillus no longer represent the most 
comron ~athogens as previously noted. This is perhaps related to lower overall need 
for s:eroids with Tacrolimus and possibly to our routine use of early post-operative 
selective enteral decontamination. 30 It was also observed that elevated serum 
creatrline and need for pre-transplant dialysis were significant predictive factors for 
post-transplant invasive fungal infectious morbidity. 30 
Cytomegalovirus (CMV) infection developed in 32% (411130) of our patients of 
which 25 were asymptomatic. Only 12% (161130) developed symptomatic CMV 
disease at a median of 45 days post-transplant. Types of symptomatic CMV disease 
included viral syndrome 44% (7116), CMV hepatitis 25% (4116), CMV enteritis 13% 
(2/16", disseminated CMV 13% (2116) and CMV retinitis 6% (1116). A relatively low 
incidence of symptomatic disease may be attributable to our high prevalence of 
seropJsitive recipients (inherently low fisk for CMV with tacrolimus containing 
regimens) and our use of short course pre-emptive ganciclovir therapy for the 
prevention of CMV disease.31 Other viral infections included cutaneous herpes 
simpoex irrections 8% (101130) and herpes zoster infections 4% (51130), all of which 
respc"dec to standard anti-viral therapy. In addition, we observed a unique clinical 
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syndrome of fever, severe thrombocytopenia, encephalopathy and vasculitis skin rash 
associated with Variant B Human Herpes Vi ru s-6. 32 This virus has been implicated 
as a pathogen in patients after bone marrow transplantation, patients with HIV and 
Iymphoproliferative diseases. 33-35 We have further hypothesized that this virus may 
represent an earty post-transplant pathogen that may be responsible for unexplained 
cytopenias or encephalitic phenomena that is often interpreted as medication related 
neurotoxicity. 
Our overall results are comparable to those recently reported and lend further 
evidence of less rejection, less overall immunosLppression and excellent patient and 
graft survival rates utilizing a primary Tacrolimus and low dose steroid 
immunosuppressive protocol. In addition, comparable rates of infectious morbidity 
were observed as compared to cyclosporine-based protocols. 
Native Portal Vein Thrombosis in U.S. Vetetans UndelTlOing Liver Ttansplantation 
It is well recognized that native portal vein thrombosis (PVT) is a significant risk 
factor for liver transplantation and that it is no longer considered a contraindication to 
the procedure. 36-41 PVT has been reported in 2.1 to 13.8% of liver transplant 
recipients. 36-42 We recently reported our observations of an inordinately high 
incidence of portal vein thrombosis in U.S. veterans undergoing transplantation. 14 We 
looked at a number of previously reported risk factors for PVT to try and elucidate the 
reason for the high incidence in our patient population. Patients reported to be a 
higher risk for PVT included males, patients with post-necrotic cirrhosis (due to ethanol 
or viral hepatitis) hypercogulable states, Budd-Chiari syndrome, etc. 35-t1 In addition 
to reporting these results we will also discuss our surgical approach. 
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Patients and Methods 
From October 1989 to February 1994, 88 U.S. veterans (87 male, 1 female) 
received 99 OL TX under primary Tacrolimus-based immunosuppression. Of these 
patients, 23 (26%) were found to have PVT either at the time of OL TX or as evident 
by pretransplant imaging studies. The classification system for grading the extent of 
PVT is shown in Table 4 the dinical parameters examined as possible risk factors for 
PVT included, age, Child's-Pugh score, underlying liver disease, liver volume, history 
of prior abdominal surgery and complications of portal hypertension. 
Results 
With a mean follow-up of 39 months (range 13 - 64 months) overall actuarial 
patient survival rates were 88, 85 and 79% at 1, 2, and 4 years respectively. The 
presence of native PVT did not influence patient survival (83% vs 88% no PVT 
1 year; 83% vs 84% 2 years, and 77% vs 81 %, four years)(Figure 2). However, poorer 
graft survival was observed in patients with PVT (Figure 2)(85% vs. 55%, 1 year; 81 % 
vs 55%, 2 years; 81 % vs 61 %, 4 years; p=O.03). None of the graft losses were 
consequence of problems with portal in-flow and four of six patients requiring re-
transplantation are currently alive and well. 
The majority of patients in both groups were either hospitalized (UNOS 3t, 57% 
with PVT 63% without PVT) or in the intensive care unit (UNOS 4t, 43% with PVT, 
32% without PVT). The average (mean) Child's-Pugh score for both groups was 12. 
The incidence of previous abdominal surgery was essentially identical (39% PVT, 38% 
no PVT) and liver size and age were also equivalent. When we examined the 
incidence of various consequences of portal hypertension (ascites, spontaneous 
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bacterial peritonitis, encephalopathy. variceal bleeding +/- sclero therapy) we found no 
significant difference between those patients with and without PVT. When dealing 
with the notoriously difficult intra-operative course of patients with PVT we employed 
a patient flexible approach to portal revascularization. We know that failure to 
establish adequate portal venous inflow is a sure recipe for patient mortality. 42 This 
was recognized early in hepatic transplantation as is evident by the routine 
procurement of vascular homografts from donors and their use for vascular 
reconstruction. 43 These grafting techniques have been well described and were 
utilized in this series of patients. 43-51 Unexpected PVT found at the time of surgery 
was not unusual and we frequently perform intraoperative portograms to better define 
the anatomy of the splanchnic inflow. Dissection of the portal vein towards the 
confluence also helps to define the extent of thrombosis however this can be quite 
difficult at times due to extensive collateralization. It is only when the extent of 
thrombosis is established (either pre-operatively or intra-operatively) that a decision 
regarding reconstruction can be made. Incomplete (grade 1) thrombosis (n=6) was 
usually detected intra-operatively, (pre-operative Doppler ultrasound invariable 
showed residual flow) and thrombectomy with end-to-end anastomotic reconstruction 
was performed in each case. Thrombectomy with end-to-end anastomosis was also 
utilized for four patients with complete thrombosis of the portal vein not extending to 
t UNOS classification system prior to April 1, 1995 
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the confluence (grade 2). More extensive thrombosis to or below the confluence of 
the superior mesenteric vein (SMV) and splenic veins (grade 3 and 4) was 
encountered in the other 13 patients. Reconstruction in these patients involved 
thrombectomy in two patients (end-to-end anastomosis), interposition vein graft (1) 
and mesoportal jump grafts (transmesocolic allogeneic iliac vein grafts from the SMV) 
in 11 patients. Patients with PVT had a significantly greater median blood loss (21 
units with PVT vs 14 units without PVT; p=0.04) and this was not unexpeded. We 
were able to use the standard veno-venous bypass in 10 thrombectomizec patients 
while single (axillo-femoral) bypass was used for the rest. 
The observed 26% incidence of PVT in our patient population is the highest 
reported in the literature to date. We concluded that our patient population had a high 
prevalence of risk factors for PVT that had been previously reported in the literature 
and that these high risk patients can be transplanted with acceptable rates of survival 
and morbidity. 
Liver Transplantation for Hepatitis C in U.S. Veterans 
End-stage liver disease secondary to hepatitis C viral infection (HVC) is 
becoming one of the leading indicators for OL TX. 52-54 HCV has been detected in 20 -
42% of the patients undergoing OL TX and it appears that perSistent post-transplant 
viremia is nearly ubiquitous. While positive HCV serology is commonly found in 
patients with alcoholic cirrhosis (37-51%), hepatitis 8 (12-53%) and cryptogenic 
cirrhosis (50%), it is rarely present in patients with primary biliary cirrhosis (PSC) or 
primary sclerosing cholangitis (PSC). 55-56 'The incidence of HCV (+/- associated 
history of ethanol abuse) induced end-stage liver disease is quite high (53%) in our 
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patient population and we are understandably concerned about recurrent disease and 
it's consequences. 15 Although we are still learning about the natural history of post-
Ol TX recurrent HCV infection, it appears histopathologic recurrence occurs in 30-70% 
of patients within the first year of post-transplantation. 52-64,57 Recent reports have 
observed progression of recurrent disease to cirrhosis and death in 15-20% one to 
three years .after transplantation. 52, s.c, 57 In s:lite of increased morbidity observed in 
those with recurrent disease the survival rates have been acce;:ltable. 57 In our 
experience, patients transplanted for HCV have the poorest ou:~me at five years 
compared to those transplanted for other dis.aases, however, tt-,e differences are not 
statistically significant. In addition, patients with histopathologic recurrence not 
unexpectedly have a lower survival rate compared to those withOut recurrence (Figs. 
3,4). Regardless of these observations, the 70-75% five year survival rates for these 
patients are quite acceptable. 
The persistence of HCV after transplantation and the pathogenesis of 
hepatocyte injury are two phenomena that yy~ are still trying to understand. Is 
hepatocyte injury an immunomediated cytotcxicity or does the ,;rus have a direct 
cytopathotic effect? Evidence supporting a direct cytopathic ef,act is the observation 
that significant pre or early post-transplant vremia is associated with rapid re-infection 
in the new allograft. s.c,58 'CytotoxiC T-Iymphocytes specific for HCV have been 
observed in patients with chronic active HCV hepatitis. The role of these cells and 
post-transplant rejection and hepatocyte injLry is not clear at ths time. 59 
The factors contributing to the rate ar·j severity of recurrent HCV are yet to be 
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fully elucidated, however, some hav: observed that the level of pre-transplant viremia, . 
virus genotype and degree of immig"D:lsup~ession appear to be important. 57,60,61 
Aggressive HCV is more commonll assocated with HCV type I-a genotype. 60 
Allograft rejection and augmented ir.rmunosuppression appeared to lead to a higher 
incidence and earlier onset of re~t HeV hepatitis. 57.61 '1-terein, we would like to 
report our experience with OL TX to· HeV ,,, our first 1 00 patients and our observation 
of increased infectio1s in patients \l':1 re::.:rrent HeV. 62 In addition, we will discuss 
current treatment strategies in the s~:ting :f rec.;rrent disease. 
Infectious Morbidity and Recurrem HCV Hepatitis 
Patients and Methods 
Between October 1989 and S:pterrber 1994, 100 consecutive U.S. veterans 
underwent OL TX under primary Ta::-olimus-based immunosuppression. Of these, 
52% were transplanted for end-sta;e liver disease due to hepatitis C. Diagnosis was 
confirmed by the presence of anti-l-t:V an:ibodies (by EIA I prior to March 1992 and 
by EIA II after March 1992) and co,;nned by a RIBA "assay. Recurrent hepatitis 
was diagnosed histopathologically 1.5ing previously reported criteria. 55,63,64 Our 
immunosuppressive protocol was tr.:-scribed eanier. Peri-operative antibiotic 
prophylaxis consisted on ampicillin :nd C;S:otaxime for 24 hours. Patients who had a 
known penicillin allergy received clrdamyon or vancomycin and aztreonam for 24 
hours. Bactrim (trimethoprim 80 m; and SJlfamethoxazole 400 mg) once daily 
indefinitely was employed for Pneu-ocysts prophylaxis. This dose was later reduced 
to thrice weekly. Aerosolized pent3lidine or da~sone was substituted for patients 
with sulfa allergies or those unable 7: tole"'3te Bactrim for other reasons. Of the 100 
patients 47 had participated in a trial comparing high dose oral acyclovir vs 7 day pre-
emptive ganciclovir (administered for CMV sheeding) for prophylaxis of CMV 
disease.31 For the remaining patients acyclovir, 600 mg daily, was administered for 
one month post-operatively as herpes simplex prophylaxis. 
Infections were defined using Centers for Disease Control (CDC) criteria. 65 < 
The diagnosis of invasive fungal infe:tions were established by positive blood culture 
or evidence of tissue invasion on bicosy or autopsy. Infections were characterized as 
either majer or minor. Included in tr·e maJ=>r infection category were bacteremia, intra-
abdomina! abscess, wound infectior perit:lnitis, invasive fungal infection, pneumonia, 
clostridium difficile colitis, cholangitis and all symptomatic CMV infections (CVM 
disease). Minor infections included mucocutaneous herpes simplex and herpes zoster 
viral infections, cystitis and asymptomatic CMV sheeding. 
We obtained surveillance cultJres for CMV (buffy coat and urine) every two 
weeks for two months then monthly for four months after transplantation. By definition 
CMV disease required the presence of symptomatology attributable to CMV in addition 
to laboratory evidence of infection. ~Ms disease was defined as previously 
reported. 3' 
Results 
The median follow-up for livirg patients was 1,083 days (range 201-1970 days) 
through March 1995. Recurrent Hey hepatitis developed in 42% (22/52) of patients 
transplanted for end-stage liver disease due to HCV or in 22% of all patients. The 
median tine to recurrence was 246 jays (range 72-994 days), 
Incidence and Type of Infections 
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Major infections occurred in 64% (14122) of the patients with recurrent HeV 
hepatitis vs 3S% (30nS) of the other patients (p = .04). Patients with recurrent HeV 
had significantly more episodes of major infections per patient as compared with other 
patients (mean 1.45 episodes per patient vs mean .51 episodes per patient, p = .003). 
In addition, patients with recurrent HeV were significantly more likely to have recurrent 
episodes of. infection. Forty-five percent of patients with recurrent HeV had more than 
one episode of major infection as compared to only 10% (SnS) of all other patients 
(p= .005). 
Major Bacterial Infections 
Although the incidence of major bacterial infection in patients with recurrent 
disease (41 %, 9122) was not significantly higher than in other patients (2S%, 22nS, 
p=NS), patients with recurrent disease had more episodes of major bacterial infections 
per patient compared to the rest (mean .S6 episodes per patient vs mean .33 
episodes per patient, p = .09). Overall, there were 19 episodes of bacterial infection 
in the 9 patients with recurrent HeV hepatitis. These included six cases of 
pneumonia, bacteremia (n=6), intra-abdominal abscess or peritonitis (n=5), and C. 
difficile colitis (n=2). The 26 episodes of bacterial infections in the other patients were 
bacteremias (n=13), intra-abdominal abscesses or peritonitis (n=7), wound infection 
(n=2), colitis (n=2) and pneumonia (n=2). 
Major Fungal Infections 
Major fungal infections were more commonly observed in patients with recurrent 
HeV hepatitis (1S% vs 6%). The observed fungal infections in patients with recurrent 
disease comprised of cryptococcosis in two (one patient had concurrent candidemia), 
1L. 
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invasive aspergillosis in one and chromoblastomycosis in one patient. In the 
remaining patients fungal infections included crytococosis in one, invasive aspergillosis 
in two (one with concurrent candidemia) and candidemia in one patient. 
Major Viral Infedions 
There were no significant differences in the incidences of CMV infection in 
patients with or without recurrent HCV however, symptomatic CMV disease occurred 
significantly more frequently in patients with recurrent disease (32% vs 9% in other 
patients, p=.012\ 
Additional Obserr'ations 
Infections occurring beyond six months post-transplant were also noted to be 
significantly higher in patients with recurrent HCV (27% vs 6% in other patients, 
p=.011). It is also notable that a higher incidence of infections was observed only in 
patients with HCV recurrence post-transplant and not in HCV positive patients who did 
not have clinical or histopathologic recurrent HCV hepatitis. Patients with HCV but 
without recurrent disease had significantly lower numbers of episodes of major 
infections, a lower incidence of major infections and a trend towards a lower incidence 
of fungal infections. There was also a trend towards less CMV disease than patients 
with clinically rerurrenl HCV hepatitis. 
Risk Factors for Infections 
In patients with recurrent HeV hepatitis compared to all other patients there 
was no observed significant difference in the severity of underlying liver disease at the 
time of transplantation as assessed by the UNOS score and Child's-Pugh score. 
We did otserve that biopsy proven rejection episodes within the first six months 
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were higher in patients with recurrent HCV hepatitis, however, the cumulative 
immunosuppression administered in born groups were not significantly different for 
patients with recurrent HCV versus all o'tler patients. When we examined late 
rejection (greater than six months post-t'ansplant) again there was no significant 
difference in the amount of immunosupp-ession. 
The r.ate of re-transplantation in patients with recurrent HCV hepatitis (median 
1083 days) was not different from that j- all other patients (9% (1/22) vs 10%, 8/78). 
Survival at the latest follow-up was 820n 18/22) for patients with recurrent HCV as 
compared with 91 % (71/78) for all othe- :Jatients (p= NS). 
Our data indicate that recurrent 'rev hepatitiS after OL TX is associated with a 
higher incidence of major infections pancularly with pathogens associated with 
depressed cell mediated immunity. 
Treatment Strategies for Recurrent He ~ after Uver Transplantation 
Recurrent HCV hepatitis post-Ol7X indeed poses a dilemma given the largely 
unsatisfactory number and efficicacy of llerapeutic options. Interferon-alpha (INF) 
suppresses HCV by a direct antiviral eff:-ct or through inhibition of viral replication. By 
increasing the MHC class I antigen exp"Sssion on hepatocytes, INF may lead to an 
enhanced cytotOXiC T-cell activity agains:: infected hepatocytes. The non-transplant 
literature reports normalization of liver e1zymes and loss of HCV RNA in 
approximately 50% of cases however Marly one half relapse upon cessation of 
therapy. 
Very little data is available regardng the safety and efficacy of interferon in the 
post-transplant setting. Two studies ha.'3 indicated that interferon therapy does not 
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appear to precipitate allograft rejection however, response to short term (6 months) of 
therapy, as defined by normalization of aminotransferases andlor diminution of HCV 
RNA levels, was disappointing (9% and 28%).66-67 These effects also appeared to be 
transient. A recent report by Feray et. al has advocated caution and concern about 
the potential for the increased risk of rejection due to upregulation of H LA antigens by 
interferon.58 _ They observed chronic rejection in five of 14 patients treated with INF 
thera;::y for recurrent disease and only a small percentage of complete responders. 
We assessed tne safety and efficicacy of a s~x month course of interferon therapy in 
18 c01secutive OL TX recipients and report the long-term response with maintenance 
therapy.69 To our knowledge no study in the post-transplant setting has evaluated the 
efficacy of long-term (greater than six months) INF therapy. 
Patient and Methods 
Recurrent HCV hepatitis developed in 42% (22/52) of patients over a five year 
period_ Four patients received less than one month of interferon and were excluded 
from the study. Eighteen patients received ~ six months of therapy and comprised the 
study sample. Recurrent HCV hepatitis was diagnosed histopathologically using 
previously defined criteria. 55,63,64 Diagnostic criteria for acute cellular rejection 
incluaed portal inflammation with large activated lymphocytes, the presence of 
eosinophils, definite bile duct damage and destruction, endotheliitis, absence of lobular 
hepatitis and hepatocyte necrosis. 
Complete response to interferon therapy was defined as normalization of both 
aspar.ate and alanine aminotransferases (AST and ALT). Early responders were 
defined as patients having a complete response within the first six months of therapy. 
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Late respon::iers were defined as patients with complete response after six months of 
therapy. Non-responders did not demonstrate a complete response either at six 
months or at the latest follow-up (median 24 months). 
Complete blood counts, liver and renal function tests, after baseline studies and 
post-operatNe recovery, were obtained monthly. Leukopenia was defined as wac 
count less r.an 2,500 and thrombocytopenia as a platelet count less than 75,000. 
Results 
The -edian follow-up period after the insttution of INF was 24 months (range 
7 -54 montt·K~ and the mean age of the study pa:ients was 48 years (range 32 - 60 
years). All :onors (except one) were seronegative for HCV. The median time to HCV 
recurrence was 192 days in a range between 30 and 1103 days. The seropositive 
donor organ was transplanted into an HCV seropositive recipient with clinical 
recurrence observed at 370 days post-transplant Fifty-five percent (10/18) of patients 
received 3 million units thrice weekly; 28% (5/18) received 5 million units thrice 
weekly; am: 16% (3/18) received 1.5 million units thrice weekly. Complete response 
at six mantiS was observed in 28% (5/18) of patients resulting in a 62% (13/18) non-
responder rnte at six months. We encouraged both responders and non-responders 
to continuenterferon therapy indefinitely. Seven patiems did not receive continued 
maintenance therapy with five patients refusing to continue therapy and 
discontinua:on of therapy due to CMV hepatitis (n=1), and leukopenia (n=1). Of the 
11 patients :ontinuing therapy, four were early responders and seven were non-
responders at six months. The patients in the early responder group who continued 
therapy (4/: all demonstrated sustained response at the latest follow-up. Of the 13 in 
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n01-res::onders. late response was observed in 46% (6/13). Of these patients four 
hs:! co~nued with maintenance therapy. While overall, only 43% (3fl) demonstrated 
a ~ng-am sustained response after six months of therapy, 73% (8/11) patients who 
ccntinu: interferon therapy beyond six months experienced a sustained response 
(p=.33) The duration of maintenance therapy ranged between 11 and 36 months 
(rredia- 21 months). 
1- :he seven long-term non-responde~I follow-up liver biopsy revealed no 
c".:ngE r two ~atients and increased lobular inflammation in five patients. The early 
a-,: la:~ -esporjers (n=11), when biopsied showed either a decrease in lobular 
imamrr-aion (314) or no change in histology (1/4). 
Sde effects of interferon therapy induded fatigue 39% (7/8), headaches and 
tranors 22% (4118) (some of which also had fatigue) and cytopenias 28% (5/18) 
(If'.Jkop:!1ia in four patients and thrombocytopenia in one patient). Rejection was 
O:seMC in S~ (1/18) of patients receiving interferon. Given that in the majority of 
pbCien~ lie did not initiate therapy until approximately six months post-transplant 
(rredia" jme to recurrent HCV) we compared the incidence of rejection occurring> six 
m:nths :ost-transplant in the patients who did not receive interferon. The incidence 
0: ,ate :> six months) rejection was 11 % (8170). 
:::ssponcers and non-responders did not differ with respect with to age, total 
biirubir. AST or AL T, re-transplantation rate or morbidity. Only one patient (non-
respon::er) required re-transplantation and expired secondary to sepsis. There were 
n: othe- mortalities. We did note a trend in non-responders to a higher baseline 
g=r1ma;Jutamr transferase (GGT) (p=O.05\ and earlier recurrence (p=.12) compared 
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with responders. In addition, responders had a significant reduction from their 
baseline GGT at six months compared to non-responders. There was no correlation 
between dosage and response. 
COndusions 
In the early 1980's the world of solid organ transplantation was revolutionized 
by the successful utilization of cyclosporine and since that time further technical 
r-efinements and improved organ preseiVation have allowed liver transplantation to 
evolve into an important and effective t~erapeutic modality for end-stage liver disease. 
1 light of the recent evidence obtai nee from large multi-center trials in both the 
United States and Europe as well as the experience at the University of Pittsburgh it 
appears that we have stepped to a higher level of refinement in immunosuppression 
and we have further improved the overall survival and quality of life of liver transplant 
recipients. This is also readily evident with the results presented herein with a group 
of high risk patients requiring transplantation. The lower incidence of rejection, less 
reliance on long-term steroid use, and comparable infectious morbidity have 
contributed to excellent patient and graft survival rates in a notably high risk group. 
With the advent of the Chiron assay in 1989 for HCV detection and evolution of 
more sophisticated detection and quan:ation methodology, HCV hepatitis is being 
recognized as a leading cause of end-stage liver disease and indication for OL TX. 70-72 
:tt is now well known that HeV perSists after transplantation and 95% (or more) 
patients remain viremic. It would seem that clinical and histologic recurrent disease is 
nevitable, however, thus far it has only been observed in 30 - 70% of patients. The 
'iatural history of this disease after transplantation will become clearer with time and 
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further investigation. Viruses such as CMV and hepatitis B have been described as 
immunomodulatory in that they appear to exert a direct immunosuppressive effect and 
facilitate super infections by other opportunistic pathogens. 73 This phenomena is well 
described with CMV n.71. and a higher incidence of septic complications has been 
observed in patients undergoing transplantation for hepatitis B. In one report 51 
HBsAg positive patients there was an overall 45% mortality with one half of these 
secondary to sepsis. Data regarding the potential immunomodulatory effect of HCV 
are sparse. One study predating HCV testing in renal transplant patients reported a 
higher incidence of life-threatening infections in patients with "non-A, non-B 
hepatitis"(NANB).75 In addition, allograft survival in patients with NANB hepatitis was 
superior suggesting again that hepatitis itself had an immunosuppressive effect. 
Unfortunately, the nature of infectious complications and other confounding variables 
such as immunosuppression were not reported. 16 Our data show that recurrent HCV 
hepatitis after transplantation is associated with a higher incidence of major infections 
and their attendant morbidity.15 While major bacterial infections did not differ between 
patients with and without recurrent HCV (41% vs 28%). fungal disease (18% vs 6%). 
and CVM disease (32% vs 9%) were distinctly more common. The increase 
susceptibility to these pathogens associated with depressed cell mediated immunity 
suggests that HCV infection has an immunomodulatory effect on the recipient. It is 
notable that this effect was apparent only in patients with histopathologically proven 
recurrent disease. Although our patients wlttl recurrent HCV had a higher incidence of 
early rejection the cumulative immunosuppressive was not significantly different from 
those without disease. 15•61 
2" 
----- ........ - ... _--_._-
There are only a few clues at present that point to a possible immunodefect 
associated with recurred HCV hepatitis. Adler et. al. reported a higher incidence of 
death in patients with parenchymal disease compared with patients with cholestatic 
disease.76't Although HCV testing was not available at the time, 67% of the patients 
with parenchymal disease had cryptogenic cirrhosis. We now know the majority of 
patients with cryptogenic cirrhosis are found to have HCV.77 Adler et. al. observed 
Significantly lower CD4 cells and CD4/8 ratios in patients with parenchymal disease. It 
is conceivable that a significant number of these patients had HCV.76 Lower CD4 
levels and increased CD8 T lymphocytes were also observed in renal transplant 
patients with NANB hepatitis.75 
Our data indicate that HCV is not only a significant cause of liver disease after 
transplantation but it is associated with a higher incidence of infections due to 
pathogens associated with depressed cell mediated immunity. Further investigation is 
needed to elucidate the effect of recurrent HCV on host defenses. In addition, since 
the propensity to increased infections appears to be a problem in patients with 
recurrent disease and not in those without clinical recurrence, efforts to prevent 
recurrence should be explored. 
Therapeutic options for recurrent HCV hepatitis atter OL TX remain largely 
unsatisfactory. In contrast to previous reports describing a poor and non-sustained 
response to IFN we observed a sustained response rate of 73% with long-term (> 6 
months) interferon therapy. We did not encounter problems with acute or chronic 
rejection as did Feray et. al. and this may be attributable to different 
immunosuppressive protocols (tacrolimus-based vs cyclosporine-based). While our 
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data were uncontrolled and our sample size was small it is still one of the largest 
reported to date in the post-transplant setting. Our data also supports a suppressive 
rather than a curative role of interferon therapy tor HCV recurrence. 
In our experience, INF in liver transplant recipients was well tolerated with 
relatively benign side-effects. Future trials should evaluate the longer courses of 
therapy for HCV recurrence until more effective anti-viral therapies become available. 
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